Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Report Predicts Huge Growth for Heart Failure Treatment Space

By Ryan Bushey | July 10, 2017

Novartis’ Entresto could lead the charge on an impressive uptick in growth for the heart failure treatment space, according to a new analysis from research and consulting firm GlobalData.

The report predicts the market value for these treatments will go from $3.7 billion in 2016 to an estimated $16.1 billion by 2026 signifying an increase of 15.7 percent in 10 years.

Entresto gained approval from the U.S. Food and Drug Administration in July 2015 after the agency reviewed data from clinical trials showing the drug could cause a 20 percent reduction in the risk of death from cardiovascular causes or hospitalization for worsening heart failure.

It was expected that this drug would be a potential blockbuster for the Swiss drugmaker, but initial sales have been modest due to factors like a $4,600 annual price in the United States.

Yet, the author of this report, Elizabeth Hamson, Ph.D., a GlobalData Healthcare analyst, writes that uptake could increase dramatically if Novartis gets regulatory approval for heart failure with preserved ejection fraction (HF-PEF) label expansion.

“Over the past two decades, chronic heart failure therapies have demonstrated success in slowing the progression of the disease and in reducing both mortality and morbidity in large-scale clinical trials. However, these successes have been limited to heart failure with reduced ejection fraction (HF-REF), showing only moderate benefits in heart failure with preserved ejection fraction (HF-PEF). Despite the lack of strong clinical evidence, guideline-recommended HF-REF therapies are widely used to treat HF-PEF,” wrote Hamson.

Cases of HF-PEF are expected to rise so this patient cohort could produce a lucrative opportunity for pharmaceutical companies like Novartis.

The company is conducting late-stage trials for HF-PEF, but Hamson expects this label expansion to be approved by 2020 if Novartis can show Entresto is an effective evidence-based therapy therefore increasing uptake.

Hamson concludes her evaluation noting there still will be a few unmet needs that would need to be addressed in the heart failure treatment space.

“Although it is thought that Entresto will fulfill a major unmet need over the forecast period, it is important to acknowledge that others will remain. For example, effective treatment of patients with multiple comorbidities, particularly those with renal impairment, will remain elusive. GlobalData does not expect this unmet need to be fulfilled during the forecast period, although the recent FDA approval of several potassium-binding agents to treat hyperkalemia may relieve the burden of this unmet need to a slight extent,” she explains.


Filed Under: Drug Discovery
Tagged With: Heart Failure Treatment
 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE